0000000000482760

AUTHOR

S. Burgio

showing 2 related works from this author

Metronomic therapy irinotecan (IRI) capecitabine (CAP) plus bevacizumab (BEV) in treatment of advanced colorectal cancer (ACRC) in very elderly peopl…

2010

Background: ACRC is one of most common neoplastic disease in very old pts. The administration of oral fluoropyrimidine (capecitabine-CAP) in a standard schedule of 1,200 mg/sqm twice a day for 14 d shows similar effects to 5-FU continuous infusion (C.I.). Furthermore, CAP- IRI showed super -additive antitumor activity. Recently many study show the safety and efficacy of a "flat dose" administration of CAP particularly in the treatment of elderly people with cancer. Also, the efficacy of BEV is well demonstrated in CRC pts. Aim of the study is to evaluate impact of bevacizumab (BEV) in combination with IRI and XEL in ACRC very old patients. Methods: 42 (20 f-22 m) elderly patients with advan…

OncologyCancer Researchmedicine.medical_specialtyScheduleBevacizumabbusiness.industryNeoplastic diseaseAdvanced colorectal cancerIrinotecanCapecitabinestomatognathic diseasesOncologyInternal medicineMedicineElderly peoplebusinessgeriatric oncologyMetronomic therapymedicine.drug
researchProduct

L'oncologia pediatrica

2012

oncologia pediatrica
researchProduct